Patients and treatments
From December 2020 through July 2022, 29 subjects were treated with sintilimab in three dose-escalating cohorts of 1 mg/kg (CONSORT diagram of the study. Out of the 32 patients initially screened, 29 were enrolled to receive sintilimab treatment. The study utilized the standard 3 + 3 design. DLT represents dose-limiting toxicityBaseline characteristics of patients